CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BENAZEPRIL HPERFORMANC	*First*	8644	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
YDROCHLORIDE TABLETS	E TESTS/ *Dissolution <711>/Test 1*	*Supplement to USP42–NF37*						*solution*: Change µg/mL to: µg/µL
TIAGABINE HYDROCHLORIDE	ASSAY/ *Procedure*	*First Supplement to USP42–NF37*	8823	26-Jul-2019	1-Aug-2019	*NA*	*NA*	In *Analysis*: Change Result = $(R_U/R_S) \times (C_S/C_U) \times$?$(M_{r1}/M_{r2}) \times$? (USP 1-Aug-2019) 100 to: Result = $(R_U/R_S) \times (C_S/C_U) \times 100$ AND Delete ?M_{r1} = molecular weight of tiagabine hydrochloride, 412.00 M_{r2} = molecular weight of tiagabine hydrochloride monohydrate, 430.02? (USP 1-Aug-2019)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM BICARBONATE	IM PURITIES/ *Carbonate*	*USP42–NF37*	4019	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Analysis*: Change and promptly add 10 g of sodium bicarbonate to: and promptly add 10 g of Sodium Bicarbonate
SAW PALMETTO EXTRACT	COMPOSITION /*Content of Long-Chain Alcohols and Sterols*	*USP42–NF37*	5196	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *System suitability stock solution B*: Change 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS and 0.37 mg/mL of stigmastanol to: 0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ETIDRONATE DISODIUM	SPECIFIC TESTS/*Water Determination <921>*	*USP42–NF37*	1745	28-Jun-2019	1-Jul-2019	*NA*	*NA*	chloroform In *Sample solution*: Change acetic acid to: glacial acetic acid
CHOLINE BITARTRATE	IM PURITIES/*Limit of Total Amines*/*System suitability*	*USP42–NF37*	4839	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Suitability requirements*: Change ?g/L. to: ?g/mL.
ACETAMINOPHEN ORAL SUSPENSION	ASSAY	*Second Supplement to USP41–NF36*	Online	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In the first *Procedure*: Change ?(Postponed on 1-Aug-2018) to:
VORICONAZOLE	IM PURITIES/ *Voriconazole*	*USP42–NF37*	4601	28-Jun-2019	1-Jul-2019	*NA*	*NA*	?(RB 1-Aug-2018) In *System suitability solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Related Compounds C and D							0.25 µg/mL of USP Voriconazole RS to: 0.25 µg/mL of USP Voriconazole RS in *Mobile phase*
SAW PALMETTO CAPSULES	IDENTIFICATION/*B. Presence of Sterols*	*USP42–NF37*	5198	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *System suitability stock solution B*: Change 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS, and 0.37 mg/mL of stigmastanol to: 0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS in chloroform

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POLYVINYL ALCOHOL	IDENTIFICATION	*USP42–NF37*	3566	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *B*: Change It meets the requirements in the test *Viscosity—Capillary Methods <911>*, *Viscosity—Rotational Methods <912>*, and *Viscosity—Rolling Ball Method <913>*. to: It meets the requirements in the test *Viscosity—Capillary Methods <911>*, *Viscosity—Rotational Methods <912>*, or *Viscosity—Rolling Ball Method <913>*.
CHOLINE CHLORIDE	IM PURITIES/*Limit of Total Amines*/*System suitability*	*USP42–NF37*	4841	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Suitability requirements*: Change ?g/L. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								?g/mL.
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official November 01, 2018)*	Online	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Test 1*/*Tolerances* and *Test 3*/*Tolerances*: Change $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O)]$ to: $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O]$
ZONISAMIDE	IMPURITIES/*Organic Impurities*	*USP42–NF37*	4675	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Analysis*: Change C_U = concentration of zonisamide related compound A in the *Sample solution* (mg/mL) to: C_U = concentration of zonisamide in the *Sample solution* (mg/mL)
CHITOSAN	ASSAY/*Degree of Deacetylation*	*USP42–NF37*	5663	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In the *Analysis*: Change Result = {1 ? [(7

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								× A_2)/(3 × A_1)] × 100 to: Result = {1 ? [(7 × A_2)/(3 × A_1)]} × 100
GUANABENZ ACETATE	IM PURITIES/*Limit of 2,6-Dichlorobenzaldehyde/Chromatographic system*	*USP42–NF37*	2129	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Column*: Change 1.8-mm × 3-mm; to: 1.8-m × 3-mm;
SUMATRIPTAN SUCCINATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4145	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Sumatriptan Succinate Related Impurities RS: Change Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide maleate salt, sumatriptan

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								succinate related compound C, [3-[2-(dimethylamino-*N*-oxide)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide. to: Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, sumatriptan succinate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								related compound C, [3 -[2-(dimethylamino-*N* -oxide)ethyl]-1*H* -indol-5-yl]-*N* -methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1*H* -indol-5-yl]-*N*-methylmethanesulfonamide.
BACILLUS COAGULANS CAPSULES	ASSAY/ *Enumeration*	*USP42–NF37*	4749	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containing to: Dispense into sterile containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
SALMETEROL INHALATION POWDER	IMPURITIES/*Organic Impurities*	*USP42–NF37*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In Row 8 of Column 1 of *Table 3*: Change Hyrdoxynaphthoic acid to: Hydroxynaphthoic acid
CLOMIPHENE CITRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1068	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Clomiphene Related Compound A RS: Change (*E*,*Z*)-2-[4-(1,2-Diphenylethyl)phenoxy]-*N*,*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-diethylethanamine hydrochloride. to: (*E*,*Z*)-2-[4-(1,2-Diphenylvinyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride. Also known as (*E*,*Z*)-2-[4-(1,2-Diphenylethenyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride.
DOXORUBICIN HYDROCHLORIDE	ASSAY/ *Procedure*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Doxorubicin Hydrochloride RS (µg/mg)
DULOXETINE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*/*Table 2*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In footnote a: Change This is a process impurity that is included in *Table 1* for identification purposes only. to: This is a process impurity that is included for identification purposes only.
PIPERAZINE PHOSPHATE	*Assay*	*USP42–NF37*	3549	31-May-2019	1-Jun-2019	*NA*	*NA*	Change Each mL of 0.1 N perchloric acid is equivalent to 7.953 mg of $C_4H_{10}N_2 \cdot 2HCl$. to: Each mL of 0.1 N perchloric acid is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								equivalent to 9.207 mg of $C_4H_{10}N_2 \cdot H_3PO_4$.
BACILLUS COAGULANS	ASSAY/ *Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
REAGENTS AND	S OL	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
REFERENCE TABLES	UTIONS/*0.02 M Edetate Disodium VS*							Change previously dried at 100° to: previously dried at 110°
CEFTIOFUR SODIUM	IM PURITIES/*High Molecular Weight Impurities*	*USP42–NF37*	859	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Analysis*: Change r_C = peak response of ceftiofur from the *Sample solution* (mg/mL) r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution* (mg/mL) to: r_C = peak response of ceftiofur from the *Sample solution* r_A = sum of the responses of all peaks that elute after ceftiofur

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								from the *Sample solution*
DIPHENHYDRAMINE HYDROCHLORIDE AND IBUPROFEN CAPSULES	ASSAY/ *Procedure*/ *Chromatographic system*/ *Detectors*	*USP42–NF37*	1402	31-May-2019	1-Jun-2019	*NA*	*NA*	Change *Identification test A*: Diode array, UV 200–400 nm to: *Identification B*: Diode array, UV 200–400 nm
DULOXETINE DELAYED-RELEASE CAPSULES	ASSAY/ *Procedure*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Buffer A*: Change monobasic sodium phosphate to: monobasic potassium phosphate AND In *Buffer B*: Change monobasic sodium phosphate to: monobasic ammonium phosphate
LEVOCARNITI	IM	*USP42–NF37*	2541	31-May-2019	1-Jun-2019	*NA*	*NA*	In the second

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NE	PURITIES/ *Enantiomeric Purity*							equation in *Analysis*: Change Result = (R_L ? P_B)/(P_A ? P_B) to: Result = (R_L ? P_B)/(P_A ? P_B) × 100
TELMISARTAN TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4206	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Telmisartan Related Compound A RS: Change 1,7’-Dimethyl-2’-propyl-1*H*,3’*H*-2,5’-bibenzo[*d*]imidazole. $C_{19}H_{20}N_4$ 304.39 to: 1,7’-Dimethyl-2’-propyl-1*H*,3’*H*-2,5’-bibenzo[*d*]imidazole

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								monohydrate. $C_{19}H_{20}N_4$? H_2O 322.41
LIQUID GLUCOSE	ASSAY/ *Reducing Sugars*	*USP42–NF37*	5741	31-May-2019	1-Jun-2019	*NA*	*NA*	In the variable definition list in *Analysis*: Change C_U = concentration of dextrose equivalent to: C_U = concentration of Liquid Glucose
ROSUVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 3*	*Revision Bulletin (Official April 01, 2019)*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Medium*: Change (dissolve 63.0 of citric acid to: (dissolve 63.0 g of citric acid
DACTINOMYCIN	IDENTIFICATION/*A. Ultraviolet Absorption <197U>/ Acceptance criteria*	*USP42–NF37*	1203	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Absorptivity*: Change The absorptivity of the *Sample solution* at 445 nm is NLT 95.0% and NMT 103.0% that of the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution. to: The absorptivity, calculated on the dried basis, of the *Sample solution* at 445 nm is NLT 95.0% and NMT 103.0% that of the *Standard solution*.
DOXORUBICIN HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the fourth equation in *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EPRINOMECTIN	IMPURITIES/*Organic Impurities/Acceptance criteria*	*USP42–NF37*	1627	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Total unknown impurities*: Change NMT 1.0 to: NMT 1.0%
SUMATRIPTAN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4139	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Sumatriptan Succinate Related Impurities RS: Change Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide maleate salt, sumatriptan succinate related compound C, [3-[2-(dimethylamino-*N*-oxid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								e)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide. to: Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, sumatriptan succinate related compound C, [3-[2-(dimethylamino-*N*-oxide)ethyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]-1*H* -indo l-5-yl]-*N* -methylmethane sulfonamide, and [3-[2-(amin oethyl)]-1*H* -indo l-5-yl]-*N*-methyl methanesulfona mide.
BACILLUS COAGULANS	ASSAY/ *Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Sample preparation* and *Analysis*: Change peptone water to: *Peptone diluent*
ARTICLES OF BOTANICAL ORIGIN	TEST FOR A FL ATO XINS/*Method I*	*USP42–NF37*	6701	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Aflatoxin standard solution*: Change ? = molecular absorptivity to: ? = molar absorptivity AND in paragraph 2 of *Aflatoxin*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard solution: Change transfer an accurate volume of each aflatoxin standard stock solution to: transfer an accurate volume of each aflatoxin stock solution
CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	897	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Cetirizine Related Compound A RS: Change 2-(2-{4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid, ethyl ester dihydrochloride. $C_{23}H_{29}ClN_2O_3 \cdot 2HCl$ 489.86 to: (*RS*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-2-[2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid ethyl ester oxalate. $C_{23}H_{29}ClN_2O_3 \cdot C_2H_2O_4$ 506.98
DIPHENHYDRAMINE HYDROCHLORIDE AND IBUPROFEN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP42–NF37*	1402	31-May-2019	1-Jun-2019	*NA*	*NA*	Change C_S = concentration of USP Diphenhydramine Hydrochloride RS and USP Ibuprofen RS in the *Standard solution* (mg/mL) to: C_S = concentration of USP Diphenhydramine Hydrochloride RS or USP Ibuprofen RS in the *Standard solution* (mg/mL)
DULOXETINE	PERFORMANC	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Test*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DELAYED-RELEASE CAPSULES	E TESTS/ *Dissolution <711>*							*3*/*Procedure*: Change 1 N sodium hydroxide VS. to: 0.1 N hydrochloric acid VS.
MILRINONE	ASSAY/ *Procedure*	*USP42–NF37*	2922	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Buffer*: Change 72.44 g of sodium tetraborate to: 72.44 g of sodium tetraborate, anhydrous
TILETAMINE HYDROCHLORIDE	*Identification*/*B. Ultraviolet Absorption <197U>*	*USP42–NF37*	4347	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Solution*: Change 0.3 mg per mL. to: 0.03 mg per mL.
REAGENTS AND REFERENCE TABLES	S OL UTIONS/*0.01 M Edetate Disodium VS*	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*: Change previously dried at 100° to: previously dried

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CEFTIOFUR HYDROCHLORIDE	IMPURITIES/*High Molecular Weight Impurities*	*USP42–NF37*	857	31-May-2019	1-Jun-2019	*NA*	*NA*	at 110° In *Analysis*: Change r_C = peak response of ceftiofur from the *Sample solution* (mg/mL) r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution* (mg/mL) to: r_C = peak response of ceftiofur from the *Sample solution* r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution*
PHENYLBUTAZONE INJECTION	*Assay*	*USP42–NF37*	3487	31-May-2019	1-Jun-2019	*NA*	*NA*	Change $350(C/V)(R_U/R_S)$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 714.3(*C*/*V*)(R_U/R_S)
DIDANOSINE	IMPURITIES/*Related Compounds*	*USP42–NF37*	1336	31-May-2019	1-Jun-2019	*NA*	*NA*	In *System suitability solution*: Change 0.5 mg/mL of of didanosine from USP Didanosine System Suitability Mixture RS in *Diluent* to: 0.5 mg/mL of USP Didanosine System Suitability Mixture RS in *Diluent*
DRONEDARONE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	1519	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Tolerances*/*30 min*: Change 20.0%–60.0% (*Q*) of the labeled amount of dronedarone free base

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 20.0%–60.0% of the labeled amount of dronedarone free base
LEVALBUTEROL INHALATION SOLUTION	IM PURITIES/*Limit of S-Albuterol*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Mobile phase*: Change ?*Acetonitrile*, *methanol*, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.? (USP 1-May-2019) to: Acetonitrile and methanol (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.
SODIUM BICARBONATE COMPOUNDE	ASSAY/ *Procedure for Sodium*	*USP42–NF37*	4023	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
D INJECTION	*Bicarbonate*							Result = [(V_S ? V_B) x N_A x F] x 100 to: Result = [(V_S ? V_B) x N_A x F x 100]/W AND Change F = equivalency factor, 84.01 mg/mL to: F = equivalency factor, 84.01 mg/mEq W = sample weight (mg)
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	*USP42–NF37*	6079	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Beef Extractl Microbial Content*: Change MT to: NMT

Pagination

- First page « First
- Previous page ‹ Previous

- …
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- …
- Next page Next ›
- Last page Last »